A nationwide trial of an investigational drug for mild to moderate Alzheimer’s disease is currently recruiting participants between the ages of 50 and 85 at more than 40 sites nationwide, including one in Chesterfield Valley.
The T2 Protect AD study will test a drug called troriluzole. The study seeks to learn if this neuroprotectant drug can slow or stop memory and thinking problems for people in that age group who already have been diagnosed with Alzheimer’s.
Troriluzole is designed to normalize a brain chemical called glutamate, which is important for healthy brain function. High glutamate levels have been shown to lead to brain cell dysfunction and disease.
The University of California, San Diego is coordinating the national trial through its Alzheimer’s Disease Cooperative Study [ADCS], one of the largest Alzheimer’s clinical trials consortiums in the country. Other participating sites include Columbia and Yale Universities as well as Johns Hopkins, Vanderbilt, Northwestern, the University of Southern California and others.
Galen Research, located at 17295 Chesterfield Airport Road, will be recruiting St. Louis area patients to participate. More information about study participation and eligibility requirements, along with local contact information, is available on the study website, t2protect.org.